Only truncated, not complete cytochrome P450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1103-1107

  McConnachie, Lisa A ^a   Phillips, Brian ^b   Bajpai, Manoj ^c   Shen, Danny D ^a   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; LIVER ENZYME;

ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOCYTE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION;

BLOTTING, NORTHERN; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; GENOTYPE; HUMANS; LYMPHOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0042357513     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1103     Document Type: Article

References (21)

1. Baron JM, Zwadlo-Klarwasser G, Jugert F, Hamann W, Rubben A, Mukhtar H, and Merk HF (1998) Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol 56:1105-1110.
2. Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, and Romkes M (1996) CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Comman Mol Pathol Pharmacol 91:149-159.
3. Coburn JW and Maung HM (2000) Calcimimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens 9:123-132.
4. Cohen A and Silverberg SJ (2002) Calcimimetics: therapeutic potential in hyperparathyroidism. Curr Opin Pharmacol 2:734-739.
5. Dey A, Parmar D, Dayal M, Dhawan A, and Seth PK (2001) Cytochrome P450 1A1 (CYP1A1) in blood lymphocytes evidence for catalytic activity and mRNA expression. Life Sci 69:383-393.
6. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, and Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445.
7. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, and Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26.
8. Hara H and Adachi T (2002) Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide. Mol Pharmacol 61:194-200.
9. Jover R, Bort R, Gomez-Lechon MJ, and Castell JV (2001) Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated anti-sense targeting. Hepatology 33:668-675.
10. Krovat BC, Tracy JH, and Omiecinski CJ (2000) Fingerprinting of cytochrome P450 and microsomal epoxide hydrolase gene expression in human blood cells. Toxicol Sci 55:352-360.
11. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagant. J Biol Chem 193:265-275.
12. Peiler G, Bockmann B, Nakhei H, and Ryffel GU (2000) Inhibitor of the tissue-specific transcription factor HNF4, a potential regulator in early Xenopus development. Mol Cell Biol 20:8676-8683.
13. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, and Carpenter SP (1997) Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 25:1429-1435.
14. Sambrook J, Fritsch EF, and Maniatis T (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
15. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
16. Vancen Heuvel JP, Clark GC, Thompson CL, McCoy Z, Miller CR, Lacier GW, and Bell DA (1993) CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 14:2003-2006.
17. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
18. Wang XY, Levy RH, and Ho RJ (2000) Development of a semi-quantitative assay to detect full-length CYP2C19 RNA. Biotechniques 29:364-370;372-373.
19. Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, and Yokoi T (1999) Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. Drug Metab Dispos 27:999-1004.
20. Yang Z, Woodahl EL, Wang XY, Bui T, Shen DD, and Ho RJ (2002) Semi-quantitative RT-PCR method to estimate full-length mRNA levels of the multidrug resistance gene. Biotechniques 33:196, 198, 200 passim.
21. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.